Russell Brown

Prof. Russell Brown

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Brain Research
Verified
Journal Article
Closed access
RBRussell Brown
Russell Brown
BKBryan Kolb
Bryan Kolb

23 April 2002 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
RBRussell Brown
Russell Brown
JGJustin T Gass
Justin T Gass
RKRichard M Kostrzewa
Richard M Kostrzewa

1 October 1996 in Experimental Neurology
Verified
Journal Article
Closed access
VSVirginia L. Smith-Swintosky
Virginia L. Smith-Swintosky
PKPhilipp J. Kraemer
Philipp J. Kraemer
ABAnnadora J. Bruce
Annadora J. Bruce
NMNicole McCants
Nicole McCants
AMAndrew Makib
Andrew Makib
MMMark Mattson
Mark Mattson

20 March 2002 in Behavioural Brain Research
Verified
Journal Article
Closed access
RBRussell Brown
Russell Brown
KBKaren S Beale
Karen S Beale
GFG.D Jay Frye
G.D Jay Frye

1 May 2021 in Behavioural Brain Research
Verified
Journal Article
Closed access
HSHeath W. Shelton
Heath W. Shelton
SGS. Prasad Gabbita
S. Prasad Gabbita
WGW. Drew Gill
W. Drew Gill
KBKatherine C. Burgess
Katherine C. Burgess
WWWyatt S. Whicker
Wyatt S. Whicker
RBRussell Brown
Russell Brown

7 November 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
WGWesley Drew Gill
Wesley Drew Gill
HSHeath W Shelton
Heath W Shelton
KBKatherine C Burgess
Katherine C Burgess
RBRussell Brown
Russell Brown
Background: Adenosine A2a receptors form a mutually inhibitory heteromeric complex with dopamine D2 receptors such that each receptor exhibits lower sensitivity to its agonist after the opposing receptor agonist is bound. This study analyzed the effects of CGS 21680, an adenosine A2A agonist, on nicotine conditioned place preference (CPP) in adolescence using a rodent model of schizophrenia (SZ). Methods: Rats were treated from postnatal day (P) 1 to P21 with saline or the dopamine D2/D3 agonist quinpirole (NQ treatment) and raised to P41. After an initial preference test, rats were conditioned with saline or nicotine (0.6 mg/kg base) from P43 to P51. CGS 21680 (0.03 or 0.09 mg/kg) was given 15 minutes before nicotine was administered. The post-conditioning test was administered on P52. On P53, the nucleus accumbens (NAcc) was analyzed for brain-derived neurotrophic factor (BDNF) and glial cell-lined neurotrophic factor (GDNF). Results: Results revealed that NQ treatment enhanced nicotine CPP, and both doses of CGS 21680 alleviated this enhancement. Nicotine also resulted in a CPP in controls, which was alleviated by both doses of CGS 21680. BDNF closely followed the behavioral results: CGS 21680 alleviated the enhancement in NAcc BDNF in NQ-treated animals, and eliminated the increase in NAcc BDNF produced by nicotine in controls. NQ-treated animals conditioned to nicotine resulted in an increase of NAcc GDNF, but this was eliminated by CGS 21680. Both BDNF and GDNF correlated with CPP performance. Conclusions: Results revealed that an adenosine A2A agonist decreased the rewarding aspects of nicotine and its accompanying neural plasticity changes in a model of SZ.